Dasatinib & Quercetin with CAR-T Cell Therapy
DART: Phase II Study of Dasatinib and Quercetin in Patients With Relapsed, Refractory Multiple Myeloma Receiving CAR-T Therapy
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 44 patients (estimated)
- Sponsors
- Mayo Clinic
- Collaborators
- National Cancer Institute (NCI)
- Tags
- CAR T Cell, Tyrosine Kinase (TK) Inhibitor, Kinase Inhibitor, Antioxidant
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2113
- NCT Identifier
- NCT06940297
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.